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anxiety disorders in 65%, ADHD in 61%, impaired social behaviour in 85%, depres-
sion in 23%, and seizures in 4%. Medical therapy for comorbidities was often 
prescribed. ConClusions: The registry is expected to provide much-needed data 
on the characteristics and management situation of FXS patients in Germany, to 
allow comparisons with other countries, and to enable gap analyses based on 
current guidelines for management of these patients. ClinTrials. gov identifier 
is NCT01711606.
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objeCtives: To conduct a systematic review of randomised controlled trials 
comparing effectiveness of GnRHa in the treatment of endometriosis in order to 
assess the feasibility of conducting a meta-analysis and indirect treatment com-
parison. Methods: Inclusion criteria were all published randomized controlled 
trials comparing GnRHa versus any other pharmacological treatment or placebo 
in the treatment of laparoscopically confirmed moderate to severe endometriosis. 
Electronic databases were searched up to February 2014 (Embase, Medline, Cochrane, 
Clintrials. gov and clinical conferences). Search results were screened, eligible stud-
ies were assessed for risk of bias and data extracted. Studies were evaluated for 
the feasibility of inclusion into a network meta-analysis. Results: A total of 1,670 
titles and abstracts were screened. Sixty-nine papers relating to 62 studies were 
identified as eligible for inclusion. Fourteen of the 62 were excluded due to high 
risk of bias, a further 21 did not present sufficient data. The remaining 27 studies 
showed clinical heterogeneity in the measurement of disease severity and efficacy 
outcomes and quality of reporting. Efficacy outcomes were measured using various 
methods and at different time points (3, 6 to 12 months). All but one measured pain, 
12 using modified versions of the Biberoglu and Behrman (B&B), 7 using a similar 
method and 4 used a visual analogue scale. Quality of life was measured in 7 studies, 
most commonly by a generic HRQoL instrument, the SF-36. Adverse event recording 
varied. ConClusions: A core set of studies were identified that could be incorpo-
rated into a quantitative analysis assessing effectiveness of GnRHa for treatment of 
moderate to severe endometriosis over 6 months. A network meta-analysis would 
potentially be feasible using more commonly reported pain outcomes, (modified) 
B&B; HRQoL and reported adverse events.
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objeCtives: The present study iims to meta-analyze clinical trials evaluating the 
efficacy of oximes on organophosphorus (OP) poisoning treatment. Methods: 
PubMed, Scopus, Google Scholar, and clinicaltials. gov were searched for studies 
investigating the effects of oximes in the treatment of OP poisoning. Mortality, 
intermediate syndrome, intensive care unit (ICU) admission rate, hospital stay dura-
tion, and intubation rate were the key outcomes of interest. Data were searched in 
the time period of 1966 through December 2013. Results: Thirteen studies (eleven 
clinical trials and two historical cohorts) that met our criteria were included in 
the analysis. Pooling of data showed that relative risk (RR) of need for intubation 
in OP poisoning for eight included trials comparing oximes with placebo was 1.27 
with 95% CI= 0.73 to 2.23 (P= 0.4). RR of only one observational study was 1.57 (95% 
CI= 0.79 to 3.2, P> 0.05). The summary of RR for mortality rate in 9 studies was 0.38 
(95% CI= 0.65 to 2.97, P= 0.41) and for one observational study was 1.33 (95% CI= 
0.54 to 3.29, P> 0.05). The RR for ICU admission rate in OP poisoning for three trials 
comparing oximes to placebo was2.12 with 95% CI= 0.89 to 5.03 (P= 0.09). For only 
one observational study, RR was 0.81 (95% CI= 0.49 to 1.25, P> 0.05). For intermediate 
syndrome, while the RR of only trial comparing oximes with placebo was 1.89 (95% 
CI= 1.27 to 2.91, P< 0.05), for only one observational study, it was 1.43 (95% CI= 0.7 
to 2.96, P> 0.05). For hospital stay duration, the RR of four studies was 0.75 with 95% 
CI = -0.51 to 1.99. ConClusions: According to these data, oximes beneficence in 
OP poisoning is unclear and there is possible increase in incidence of intermediate 
syndrome.
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objeCtives: The number of women whose labours are induced is increasing with 
average rates in England in excess of 20%. A broad range of methods for induction 
are available, including pharmacological, mechanical and alternative interventions 
with considerable variation in effectiveness, safety and cost. Of the pharmaco-
logical interventions, the most commonly used are prostaglandins. However, even 
within this class, there are a variety of different prostaglandins with a variety of 
modes of administration. The aim of this piece of work is to identify the most cost-
effective and safe prostaglandin for cervical ripening and labour induction in the 
NHS setting. Methods: A systematic review and network meta-analysis (NMA) of 
all relevant randomised trials comparing all prostaglandins for labour induction, 
and a cost-effectiveness analysis represented in the form of a decision tree model 
incorporating cost and maternal and neonatal health outcomes. Results: The NMA 
of randomised controlled trials comparing 11 different types of prostaglandins for 
labour induction demonstrated that the best treatment for achieving a vaginal birth 
within 24 hours was vaginal misoprostol tablet ≥ 50μ g with a probability of being 
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objeCtives: Adverse drug event (ADEs), hospitalizations, and emergency department 
(ED) visits are important sequelae of inappropriate prescribing. Explicit measures are 
useful methods to detect inappropriate prescribing in the elderly. This study com-
pares the predictive validity of the 2002 Beers, 2012 Beers, and the STOPP criteria 
for these outcomes. Methods: A retrospective cohort design was implemented 
using commercial claims data between 2006 and 2009. Subjects included those 65 
years and older continuously eligible for medical and pharmacy benefits for at least 
6 months to assess baseline comorbidities and 3 months of follow-up. Time vary-
ing cox proportional hazard models were estimated using a monthly time interval 
where indicators of inappropriate prescribing exposure in month (i-1) where related 
to outcomes in month (i) to minimize temporal ambiguity between exposure and 
outcome. Measures of model discrimination (c-index) and hazard ratios (HR) were 
calculated to compare un-adjusted and adjusted models with the 2002 Beers, 2012 
Beers, and STOPP exposures models. Results: The final cohort included 174,275 
contributing 361,621 person years of follow up. The prevalence of inappropriate pre-
scribing was 34.1%, 32.2%, and 27.6% for the 2012 Beers, 2002 Beers, and the STOPP 
criteria and the rates of ADEs, ED, and hospital visits were 21.0, 140.3, 67.2 per 1000 
person years. All inappropriate prescribing criteria modestly discriminated ADEs 
in unadjusted analyses: STOPP (HR= 2.89 [2.68-3.12]; C-index= 60.7%), 2012 Beers 
(HR= 2.51 [2.33-2.70]; C-index= 60.3%), 2002 Beers (HR= 2.65 [2.46-2.85]; C-index= 60.5%). 
Similar results for model discrimination measures were observed for ED visits (STOPP 
[C-index= 59.0%], 2012 Beers [C-index= 58.5%], 2002 Beers [C-index= 58.5%]) and 
hospitalizations (STOPP [C-index= 59.8%], 2012 Beers [C-index= 59.0%], 2002 Beers 
[C-index= 58.8%]). ConClusions: All three of the criteria were modestly prognostic 
for ADEs, EDs, and hospitalizations with the STOPP criteria slightly outperforming the 
Beers criteria. Inappropriate prescribing is common in the elderly and significantly 
increases the risk of subsequent hospitalizations, ED visits, and ADEs.
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objeCtives: In Germany, the share of persons aged > 65 years is 21%. Germany there-
fore has the highest share of older inhabitants compared to other european coun-
tries. The aim of the present study was to evaluate the prevalence of defined chronic 
diseases among older patients (> 65 years) in German general practitioner (GP) prac-
tices. Methods: Data from Disease Analyzer database including 1,100 GPs were used. 
2,722,706 patients with at least one consultation in the time between April 2013 and 
March 2014 were included and analyzed. Results: Overall, 774,361 (28.4%) of patients 
by GPs were over 65 years. In patients aged > 65 years 66% were diagnosed with hyper-
tension, 41% with lipid metabolism, 33% with diabetes mellitus, 29% with coronary 
heart disease, 20% with rheumatoid arthritis, 19% with cancer, 15% with chronic 
obstructive pulmonary disease and 14% with heart insufficiency. ConClusions: 
Patients older than 65 years make up 28% and therefore comprise the main client 
group of GPs. The prevalence of chronic diseases is in this age very high. On account 
of their multimorbidity, the care of these patients is challenging. It is therefore impor-
tant to place particular emphasis on geriatric patient care as a part of the study of 
medicine as well as in physicians assistant degree programs.
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objeCtives: The Fragile X syndrome (FXS), caused by a CGG repeat expansion 
in the FMR1 gene on the X chromosome, is the most common inherited form of 
mental retardation and autism. Representative data on the characteristics and 
management of FXS patients in Germany are lacking. Methods: EXPLAIN FXS 
is an ongoing prospective longitudinal observational study which evaluates char-
acteristics and management of patients with a genetically confirmed diagnosis of 
FXS in ambulatory care. The registry uses a non-probability sampling approach to 
collect data on the characteristics, therapeutic drug and non-drug interventions, 
psychosocial parameters, quality of life, caregiver burden, and health economic 
parameters such as hospitalisation days. Results: After an average 9-month 
recruitment period in 10 centres, 33 patients have been included (86% males, 
mean age 22 years, age range 2- 82 years). Only 1 and 4 patient attended regular 
school, or regular school with integration measures, whereas the others were in 
special schools for the mentally impaired. Siblings were affected by FXS in 59% 
(10% unknown). On the 6-item FXS disease score by Giangreco (on 25 patients), 
the mean value was 6.7 ±2.4 points (range 2.4 to 11.0). Autistic behaviour was 
noted in 89%, hyperactivity in 50%, impaired intelligence in 96%. An FXS phe-
notype was often met, as 63% of patients were described to have a long, narrow 
face, and 89% large or prominent ears. Comorbidities were frequent, in particular 
